Targeting Alpha-Synuclein: Breakthroughs in the Quest to Halt Parkinson's Progression
By A Mystery Man Writer
Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases - ScienceDirect
IJMS, Free Full-Text
PDF) Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application
Targeted degradation of ⍺-synuclein aggregates in Parkinson's disease using the AUTOTAC technology, Molecular Neurodegeneration
What is coming in 2024 for Parkinson's Biological Definitions, Staging and Classification? — Parkinson Secrets
Biomolecules, Free Full-Text
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Mechanisms of alpha-synuclein toxicity: An update and outlook - ScienceDirect
IJMS, Free Full-Text
Vaxxinity Demonstrates Target Engagement of Toxic
IJMS, Free Full-Text
Pharmaceutics, Free Full-Text
Frontiers Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson's Disease
PDF] The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease
PDF) Alpha-synuclein oligomers: a new hope
